Michael P. Diamond

Michael P. Diamond

Auto-generated profile, based on publicly available information

Michael P. Diamond

Augusta University, 1120 15th Street, Augusta, GA 30912, USA

Research Focus & Metrics

Academic Career Length

49Years (1978-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2007 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
RLRichard S. Legro
Richard S. Legro
HBHuiman X. Barnhart
Huiman X. Barnhart
WSWilliam D. Schlaff
William D. Schlaff
BCBruce R. Carr
Bruce R. Carr
MDMichael P. Diamond
Michael P. Diamond
EMEvan R. Myers
Evan R. Myers
The polycystic ovary syndrome is a common cause of infertility. Clomiphene and insulin sensitizers are used alone and in combination to induce ovulation, but it is unknown whether one approach is superior.

10 July 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
RLRichard S. Legro
Richard S. Legro
RBRobert G. Brzyski
Robert G. Brzyski
MDMichael P. Diamond
Michael P. Diamond
CCChristos Coutifaris
Christos Coutifaris
WSWilliam D. Schlaff
William D. Schlaff
HZHeping Zhang
Heping Zhang
Clomiphene is the current first-line infertility treatment in women with the polycystic ovary syndrome, but aromatase inhibitors, including letrozole, might result in better pregnancy outcomes. In this double-blind, multicenter trial, we randomly assigned 750 women, in a 1:1 ratio, to receive letrozole or clomiphene for up to five treatment cycles, with visits to determine ovulation and pregnancy, followed by tracking of pregnancies. The polycystic ovary syndrome was defined according to modified Rotterdam criteria (anovulation with either hyperandrogenism or polycystic ovaries). Participants were 18 to 40 years of age, had at least one patent fallopian tube and a normal uterine cavity, and had a male partner with a sperm concentration of at least 14 million per milliliter; the women and their partners agreed to have regular intercourse with the intent of conception during the study. The primary outcome was live birth during the treatment period. Women who received letrozole had more cumulative live births than those who received clomiphene (103 of 374 [27.5%] vs. 72 of 376 [19.1%], P=0.007; rate ratio for live birth, 1.44; 95% confidence interval, 1.10 to 1.87) without significant differences in overall congenital anomalies, though there were four major congenital anomalies in the letrozole group versus one in the clomiphene group (P=0.65). The cumulative ovulation rate was higher with letrozole than with clomiphene (834 of 1352 treatment cycles [61.7%] vs. 688 of 1425 treatment cycles [48.3%], P<0.001). There were no significant between-group differences in pregnancy loss (49 of 154 pregnancies in the letrozole group [31.8%] and 30 of 103 pregnancies in the clomiphene group [29.1%]) or twin pregnancy (3.4% and 7.4%, respectively). Clomiphene was associated with a higher incidence of hot flushes, and letrozole was associated with higher incidences of fatigue and dizziness. Rates of other adverse events were similar in the two treatment groups. As compared with clomiphene, letrozole was associated with higher live-birth and ovulation rates among infertile women with the polycystic ovary syndrome. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and others; ClinicalTrials.gov number, NCT00719186.)

1 September 1981 in Metabolism
Verified
Journal Article
Closed access
NANaji N. Abumrad
Naji N. Abumrad
DRDavid Rabin
David Rabin
MDMichael P. Diamond
Michael P. Diamond
WLWilliam W. Lacy
William W. Lacy

13 May 2004 in Nature
Verified
Journal Article
Open access
PDF file
GOG. Charles Ostermeier
G. Charles Ostermeier
DMDavid Miller
David Miller
JHJohn D. Huntriss
John D. Huntriss
MDMichael P. Diamond
Michael P. Diamond
SKStephen A. Krawetz
Stephen A. Krawetz
Even though the genetic fingerprint of human sperm has been defined, its role in orchestrating fertilization and the development of the early embryo remains vague. Here we show that human male gametes pass over more to the oocyte than just the haploid male genome — paternal messenger RNAs are also delivered to the egg at fertilization. If these transcripts, previously thought to be left-overs from spermatogenesis, are important in early development, our findings may have implications for the success of somatic-cell nuclear transfer in cloning technology and the identification of components leading to unexplained male-factor infertility.

11 October 2011 in Human Reproduction
Verified
Journal Article
Closed access
SKStephen A. Krawetz
Stephen A. Krawetz
AKAdele Kruger
Adele Kruger
CLClaudia Lalancette
Claudia Lalancette
RTRebecca Tagett
Rebecca Tagett
EAEster Anton
Ester Anton
MDMichael P. Diamond
Michael P. Diamond
There has been substantial interest in assessing whether RNAs (mRNAs and sncRNAs, i.e. small non-coding) delivered from mammalian spermatozoa play a functional role in early embryo development. While the cadre of spermatozoal mRNAs has been characterized, comparatively little is known about the distribution or function of the estimated 24,000 sncRNAs within each normal human spermatozoon. RNAs of <200 bases in length were isolated from the ejaculates from three donors of proved fertility. RNAs of 18-30 nucleotides in length were then used to construct small RNA Digital Gene Expression libraries for Next Generation Sequencing. Known sncRNAs that uniquely mapped to a single location in the human genome were identified. Bioinformatic analysis revealed the presence of multiple classes of small RNAs in human spermatozoa. The primary classes resolved included microRNA (miRNAs) (≈ 7%), Piwi-interacting piRNAs (≈ 17%), repeat-associated small RNAs (≈ 65%). A minor subset of short RNAs within the transcription start site/promoter fraction (≈ 11%) frames the histone promoter-associated regions enriched in genes of early embryonic development. These have been termed quiescent RNAs. A complex population of male derived sncRNAs that are available for delivery upon fertilization was revealed. Sperm miRNA-targeted enrichment in the human oocyte is consistent with their role as modifiers of early post-fertilization. The relative abundance of piRNAs and repeat-associated RNAs suggests that they may assume a role in confrontation and consolidation. This may ensure the compatibility of the genomes at fertilization.

18 August 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
MHM Geoffrey Hayes
M Geoffrey Hayes
MUMargrit Urbanek
Margrit Urbanek
DEDavid A. Ehrmann
David A. Ehrmann
LALoren L. Armstrong
Loren L. Armstrong
JLJi Young Lee
Ji Young Lee
ADAndrea Dunaif
Andrea Dunaif
Polycystic ovary syndrome (PCOS) is a common, highly heritable complex disorder of unknown aetiology characterized by hyperandrogenism, chronic anovulation and defects in glucose homeostasis. Increased luteinizing hormone relative to follicle-stimulating hormone secretion, insulin resistance and developmental exposure to androgens are hypothesized to play a causal role in PCOS. Here we map common genetic susceptibility loci in European ancestry women for the National Institutes of Health PCOS phenotype, which confers the highest risk for metabolic morbidities, as well as reproductive hormone levels. Three loci reach genome-wide significance in the case–control meta-analysis, two novel loci mapping to chr 8p23.1 and chr 11p14.1, and a chr 9q22.32 locus previously found in Chinese PCOS. The same chr 11p14.1 SNP, rs11031006, in the region of the follicle-stimulating hormone B polypeptide (FSHB) gene strongly associates with PCOS diagnosis and luteinizing hormone levels. These findings implicate neuroendocrine changes in disease pathogenesis.